MetaCap

BridgeBio Pharma (BBIO) vs Elanco Animal Health (ELAN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Elanco Animal Health (ELAN) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 15.7% versus a gain of 11.6%. Over five years, BBIO leads with a +92.2% price change compared with -14.8% for ELAN. BridgeBio Pharma is the larger company by market cap ($14.81 billion vs $12.87 billion), about 1.2 times the size.

Elanco Animal Health converts more of its revenue into profit, with a net margin of -4.9% versus -146.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBIO+11.63%ELAN+15.69%
+35%+11%-13%
Nov 21, 20251 yearNov 20, 2026
BBIO+78.26%ELAN-19.84%
+111%+8%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBIO versus ELAN key metrics
MetricBBIOELAN
Share price$76.03$25.74
Market cap$14.81B$12.87B
1-day change-2.75%-2.09%
YTD return-0.60%+13.74%
1-year return+11.63%+15.69%
5-year return+92.24%-14.82%
Forward P/E—19.91
EPS (TTM)$-3.03$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$502.08M$4.71B
Revenue growth (YoY)+126.26%+6.22%
Net income (latest FY)$-732.94M$-232.00M
Gross margin95.82%54.99%
Operating margin-104.25%—
Net margin-145.98%-4.92%
52-week high$93.42$27.98
52-week low$62.50$19.40
Distance from 52-week high-18.61%-8.01%
Analyst consensusstrong_buybuy
Avg. price target upside+40.73%+20.44%
Average volume2.67M5.32M
Shares outstanding194.80M499.83M
Employees1,0819,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Elanco Animal Health is more profitable, keeping -4.9 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
  • BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +6.22%).

About BridgeBio Pharma

BBIO stock →

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees

About Elanco Animal Health

ELAN stock →

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.

Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees

BBIO vs ELAN FAQ

Which is bigger, BridgeBio Pharma or Elanco Animal Health?

BridgeBio Pharma (BBIO) is larger, with a market capitalization of $14.81B compared with $12.87B for Elanco Animal Health (ELAN).

Which stock has performed better over the past year, BBIO or ELAN?

ELAN returned +15.69% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.

Are BridgeBio Pharma and Elanco Animal Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons